Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2008-06-17
2008-06-17
Zeman, Robert A. (Department: 1645)
Chemistry: molecular biology and microbiology
Vector, per se
C536S023700, C536S025600, C435S258200, C424S278100, C424S093200, C424S093100
Reexamination Certificate
active
07387894
ABSTRACT:
The present invention relates to novel vaccines against malaria infections, based on recombinant viral vectors, such as alpha viruses, adenoviruses or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against differentPlasmodiuminfections, such as infections byP. falciparumorP. yoelii. Novel codon-optimized circumsporozoite genes are disclosed. Preferably, replication-defective adenoviruses are used, derived from serotypes that encounter low titers of neutralizing antibodies. The invention, therefore, also relates to the use of different adenoviral serotypes that are administered to elicit a strong immune response, either in single vaccination set-ups or in prime-boost set-ups in which compositions based on different serotypes can be applied.
REFERENCES:
patent: 6306625 (2001-10-01), Jacobs et al.
patent: 99201545.3 (1999-05-01), None
patent: 0 978 566 (2000-02-01), None
patent: 1 054 064 (2000-11-01), None
patent: WO 93/10152 (1993-05-01), None
patent: WO 96/26281 (1996-08-01), None
patent: WO 96/39178 (1996-12-01), None
patent: WO 97/00326 (1997-01-01), None
patent: WO 98/32842 (1998-07-01), None
patent: WO 98/50053 (1998-11-01), None
patent: WO 99/55132 (1999-11-01), None
patent: WO 99/64582 (1999-12-01), None
patent: WO 00/03029 (2000-01-01), None
patent: WO 00/52186 (2000-09-01), None
patent: WO 00/70071 (2000-11-01), None
patent: WO 01/02607 (2001-01-01), None
patent: WO 01/05945 (2001-01-01), None
patent: WO 01/07571 (2001-02-01), None
patent: WO 02/22080 (2002-03-01), None
patent: WO 02/24730 (2002-03-01), None
patent: WO 02/40665 (2002-05-01), None
patent: WO 2004/055187 (2004-07-01), None
De Jong et al., Adenoviruses from Human Immunodeficiency Virus-Infected Individuals, Including Two Strains That Represent New Candidate Serotypes Ad50 and Ad51 of Species B1 and D, Respectively, Journal of Clinical Microbiology, Dec. 1999, pp. 3940-3945, vol. 37, No. 12.
Gandon et al., Imperfect vaccines and the evolution of pathogen virulence, Nature, Dec. 13, 2001, pp. 751-756, vol. 414.
Moran et al., Requirements for Glycosylphosphatidylinositol Attachment Are Similar but Not Identical in Mammalian Cells and Parasitic Protozoa, The Journal of Cell Biology, Apr. 1994, pp. 333-343, vol. 125, No. 2.
Nardin et al., A Totally Synthetic Polyoxime Malaria Vaccine ContainingPlasmodium falciparumB Cells and Universal T Cell Epitopes Elicits Immune Responses in Volunteers of Diverse HLA Types, The Journal of Immunology, 2001, pp. 481-489, vol. 166.
Nussenzweig et al., Protective Immunity produced by the Injection of X-irradiateed Sporozoites ofPlasmodium berghei,Nature, Oct. 14, 1967, pp. 160-162, vol. 216.
Rodrigues et al., Single Immunizing Dose of Recombinant Adenovirus Efficiently Induces CD8+ T Cell-Mediated Protective Immunity Against Malaria, The Journal of Immunology, 1997, pp. 1268-1274, vol. 158.
Romero et al., Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria, Nature, Sep. 28, 1989, pp. 323-326, vol. 341.
Scheiblhofer et al., Removal of the circumsporozoite protein (CSP) glycosylphosphatidylinositol signal sequence from a CSP DNA vaccine enhances induction of CSP-specific Th2 type immune responses and improves protection against malaria infection, Eur. J. Immunol., 2001, pp. 692-698, vol. 31.
Bruna-Romero et al., Detection of malaria live-stages in mice infected through the bite of a single Anopheles mosquito using a highly sensitive real-time PCR, International Journal of Parasitology, 2001, pp. 1499-1502, vol. 31.
Kurtis et al., Pre-erythrocytic immunity toPlasmodium faleiparum: the case for an LSA-I vaccine, Trends in Parasitology, May 2001, pp. 219-223, vol. 17, No. 5.
Lock Yer et al., Wild isolates ofPlasmodium faleiparumshow extensive polymorphism in T cell epitopes of the circumsporozoite protein, Molecular and Biochemical Parasitology, 1989, pp. 275-280, vol. 37.
#Basler et al., “Sequence of the immunoregulatory early region 3 and flanking sequences of adenovirus type 35,” Gene, 1996, pp. 249-254, vol. 170.
#Benmohamed et al., “High immunogenicity in chimpanzees of peptides and lipopeptides derived from four newPlasmodium falciparumpre-erythrocytic molecules,” Jun. 2000, pp. 2843-2855, vol. 18, No. 25.
#Bruna-Romero et al., “Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen,” Proc. Natl. Acad. Sci. USA, Sep. 25, 2001, pp. 11491-11496, vol. 98, No. 20.
#Daubersies et al., “Protection againstPlasmodium falciparummalaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3,” Nature Medicine, Nov. 2000, pp. 1258-1263, vol. 6, No. 11.
#Flomenberg et al., “Molecular Epidemiology of Adenovirus Type 35 Infections in Immunocompromised Hosts,” The Journal. of Infectious Diseases, Jun. 1987, pp. 1127-1134, vol. 155, No. 6.
#Flomenberg et al., “Sequence and genetic Organization of Adenovirus Type 35 Early Region 3,” Journal of Virology, Nov. 1988, pp. 4431-4437, vol. 62, No. 11.
#Gahery-Segard et al., “Immune response to recombinant Capsid Proteins of Adenovirus in Humans: Antifiber and Anti-Penton Base Antibodies Have a Synergistic Effect on Neutralizing Activity,” Journal of Virology, Mar. 1998, pp. 2388-2397, vol. 72, No. 3.
#Kang et al., “Molecular Cloning and Physical Mapping of the DNA of Human Adenovirus Type 35,” Acta Microbiologica Hungarica, 1999, pp. 67-75, vol. 36, No. 1.
#Krasnykh et al., “Generation of Recombinant Adenovirus Vectors with modified Fibers for Altering Viral Tropism,” Journal of Virology, Oct. 1996, pp. 6839-3846, vol. 70, No. 10.
#Miyahira et al., “Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice,” Proc. Natl. Acad. Sci. USA, Mar. 31, 1998, pp. 3954-3959, vol. 95, No. 7.
#Nagata et al., “Codon Optimization Effect on Translational Efficiency of DNA Vaccine in Mammalian Cells: Analysis of Plasmid DNA Encoding a CTL Epitope Derived from Microorganisms,” Aug. 2, 1999, pp. 445-451, vol. 261, No. 2
#Narum et al., “Codon Optimization of Gene Fragments EncodingPlasmodium falciparumMerzoite Proteins Enhances DNA Vaccine Protein Expression and Immunogenicity in Mice,” Dec. 2001, pp. 7250-7253vol. 69, No. 12.
#Notice of Opposition to a European Patent, Patent No. 1054064, by Cell Genesys Inc., dated Jul. 5, 2005.
#PCT International Preliminary Examination Report, PCT/EP03/51019, dated Mar. 22, 2005.
#PCT International Search Report, PCT/EP03/51019, dated Jun. 9, 2004.
#Rosenfeld et al., Adenovirus-Mediated Transfer of a recombinant alpha-1-Antitrypsin Gene to the Lung Epithelium in Vivo, Science, Apr. 19, 1991, pp. 431-434, vol. 252.
#Roy et al., “Circumvention of Immunity to the Adenovirus major Coat Protein Hexon,” Journal of Virology, Aug. 1998, pp. 6875-6879, vol. 72, No. 8.
#Scheiblhofer et al., “Removal of the circumsperosoite protein (CSP) glycosylphosphatidylinositol signal sequence from a CSP DNA vaccine enhances induction of CSP-specific Th2 type immune responses and improves protection against malaria infection,” Eur. J. Immunol., Mar. 2001, pp. 692-698, vol. 31, No. 3.
#Singh et al., “Advances in vaccine adjuvants,” Nature Biotechnology, 1999, pp. 1075-1081, vol. 17.
#Soares et al., “Malaria vaccine: roadblocks and possible solutions,” Brazilian Journal of Medical and Biological Research, 1998, pp. 317-332, vol. 31.
#Stevenson et al., “Human Adenovirus Serotypes 3 and 5 Bind to Two Different Cellular receptors via the Fiber Head Domain,” Journal of Virology, May 1995, pp. 2850-2857, vol. 69, No. 5.
#Stratford-Perricaudet et al., “Evaluation of the Transfer and Expression in Mice of an Enzyme-Encoding Gene Using a Human Adenovirus Vector,” Human Gene Therapy, 1990, pp. 241-256, vol. 1.
#Tine et al., “NYVAC-Pf7: a Po
Holterman Lennart
Kaspers Jorn
Pau Maria G.
Stegmann Antonius J. H.
Crucell Holland B.V.
Tongue Lakia J
TraskBritt
Zeman Robert A.
LandOfFree
Recombinant viral-based malaria vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant viral-based malaria vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant viral-based malaria vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2814881